Can an oral antidiabetic (rosiglitazone) be of benefit in leukemia treatment?
Küçük Resim Yok
Tarih
2015
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Elsevier Science Bv
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
PPARs are ligand-regulated transcription factors and regulate expression of several gene products. Therefore, PPARs are being studied for their possible contribution to the treatment of cancer, atherosclerosis, inflammation, infertility and demyelinating diseases. Primary AML patients were observed to have significantly elevated PPAR gamma mRNA expression compared to normal peripheral blood or bone marrow mononuclear cells. This study investigated the cytotoxic effects of rosiglitazone maleate, a pure PPAR gamma agonist, in vitro in HL-60 cell line. This study obtained results which can provide guidance for future studies. Whether the PPARy agonist rosiglitazone maleate may provide additive effects in refractory or relapsing cases of acute leukemia may be set as an objective for the future studies. (C) 2013 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
Açıklama
Anahtar Kelimeler
Rosiglitazone maleate, PPAR, Acute leukemia, HL 60 cell line
Kaynak
Saudi Pharmaceutical Journal
WoS Q Değeri
Q3
Scopus Q Değeri
Q2
Cilt
23
Sayı
1
